繁體
简体中文
繁體中文

biote BTMD 深 滬

已收盤 11-20 16:00:00 美东时间

0.8147

-0.030

-3.56%

华盛通華盛通
立即下載
  • 最 高0.85
  • 今 開0.82
  • 成交量 3.78万股
  • 最 低 0.81
  • 昨 收 0.8448
  • 總市值 2922.94万
  • 52周最高 2.90
  • 市盈率 靜 1.10
  • 換手率 0.11%
  • 52周最低 0.81
  • 委 比 97.70%
  • 總股本 3587.75万
  • 歷史最高 12.08
  • 量 比 0.55
  • 振 幅 4.73%
  • 歷史最低 0.81
  • 每 手 1
  • 風險率 0.52%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Thermo Fisher Scientific (TMO) Beat Estimates And Launched VaxEvo, Is An 11% Discount Enough?

    Why Thermo Fisher Scientific Stock Is Back in Focus Thermo Fisher Scientific (TMO) just paired strong third quarter earnings that topped analyst expectations with the launch of its Gibco VaxEvo CD 293 Medium for higher efficiency adenovirus vaccine production. Thermo Fisher Scientific’s recent catalysts, including the VaxEvo CD 293 launch and a high profile CEO appearance at the UBS 2026 conference on 19 November, come against a mixed backdrop. T

    11-21 23:11

  • What Could Moderna (MRNA) Gain From Australia Reviewing Its MRNA Flu Vaccines?

    Moderna (NasdaqGS:MRNA) is on the Australian PBAC agenda as its mRNA flu vaccines are assessed for National Immunisation Program listing. The PBAC review focuses on potential government funding that could support wider public access to Moderna's mRNA flu portfolio in Australia. The evaluation puts Moderna's non COVID pipeline in front of a key international reimbursement body for seasonal influenza prevention. The PBAC review of Moderna's mRNA fl

    11-21 18:09

  • What Natera Holders Bought Into

    If Natera sat on your watchlist instead of in your account over the past year, the outcome may feel like a missed shot. Investors who held Natera over the past year are up 28.5%, including dividends. That move came as the diagnostics group pushed further into personalized medicine built on AI and molecular residual disease testing. The real puzzle is whether investors could reasonably have spotted that this business model, and not just another bi

    11-21 05:16

  • Missed Exelixis's Run? What Holders Had To Believe

    If you had bought Exelixis on 19 November 2025 and simply sat tight, the outcome would look very different today. Holding Exelixis over the past year would have returned 57.6%, including dividends. That headline invites a harder question. At the time, you were staring at an oncology specialist tied closely to cabozantinib, rising 340B pressure, and an unproven zanzalintinib franchise. If you were weighing that decision then, how much conviction c

    11-21 04:08

  • Exicure Announces Strategic Expansion and Investment Agreement for X-CUE

    Exicure ( ($XCUR) ) has shared an update. Exicure is a biotechnology company fo...

    11-21 02:27

  • Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

    Capricor Therapeutics received a Complete Response Letter (CRL) from the FDA for its resubmitted BLA for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD). The FDA stated the data did not establish substantial evidence of effectiveness and cited clinical deficiencies. The company expressed disappointment but emphasized the rigor of its clinical program and plans to review the letter and provide next steps. Capricor also announced a...

    11-21 00:55

  • How Much Merck Do You Really Get Through 3 ETFs?

    Owning Merck directly means you carry company specific issues by yourself, such as a dividend that Simply Wall St says is not well covered by earnings, or profit margins that Simply Wall St notes are much slimmer than last year. Holding Merck inside a fund that also owns other healthcare businesses spreads out how much those Merck specific swings can move your portfolio. It also reduces the impact of any positive surprise from Merck on its own. T

    11-20 23:12

  • Purple Biotech Announces IM1240 Data From Plenary EORTC-NCI-AACR Presentation

    The latest update is out from Purple Biotech ( ($PPBT) ). Purple Biotech is a b...

    11-20 22:28

  • Which ETFs Give You GE Vernova As Poland Weighs Nuclear Support?

    When you buy GE Vernova directly, your results move with everything that happens to this one business. Simply Wall St flags risks such as large one off items that can affect reported figures, and pressure on onshore wind equipment from permitting delays and tariff uncertainty. Owning GE Vernova through an exchange traded fund spreads those specific issues across many holdings. This also means any potential upside from the stock is shared with the

    11-20 22:10

  • Abivax Statement on Short Seller Report

    Abivax SA issued a statement addressing a report by Scorpion Capital, which the company claims contains factually inaccurate and misleading statements. Abivax emphasizes the integrity of its clinical data, particularly from its Phase 3 ABTECT trials, and plans to file an NDA with the U.S. FDA by year-end. Scorpion Capital disclosed a short position in Abivax, highlighting its financial incentive to lower the company's share price. Abivax is a cli...

    11-20 21:33